Home
overview

The fast-moving and ever-changing world market for anti-infective drugs will be the subject of SMi’s seventh annual Superbugs and Superdrugs Conference.  This year’s event will centre around the evaluation of current developments, in terms of advances in drug discovery, the success of recently implemented projects and pipeline developments.

Issues surrounding Anti-Fungal, Antibacterial and Anti-Viral medications worldwide, will give this year’s event a fantastic cross-section of topics which will help to unearth the hot topics, regulatory issues and outstanding progressions within their respective fields.  With the value of the world market in infectious disease drugs standing at around $20bn, both large and small pharma and biotech companies are taking advantage of the current market conditions, creating a very focussed yet diverse approach.

Your attendance will allow you to benefit from the knowledge of top industry experts and enhance your understanding across many different areas.  This in turn will ensure that you are in the best position to make decisions and judgements on the market, as well as supplying you with direct access to some of the major players currently in your sector.

Benefit from the knowledge of:

  • Dr André Bryskier, Head, Clinical Pharmacology, Anti-Infectives, Sanofi-Aventis
  • Dr Anita Howe, Associate Director, Infectious Diseases, Wyeth
  • Dr Kathryn Bracken, Associate Director, Novartis
  • Dr Dean Stamos, Associate Director, Chemistry, Drug Discovery, Vertex Pharmaceuticals
  • Dr Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene
  • Dr Heike Brötz-Oesterhelt, Senior Scientist, Antibacterial Research, Bayer Healthcare
  • Dr Hans-Henrik Kristensen, Head, Anti-Infective Discovery, Novozymes
  • Dr William Weiss, Director, Drug Evaluation, Cumbre

The essential event on:

  • CURRENT PROGRESS IN ANTIBIOTIC RESEARCH: Learn about a unique antibiotic discovery engine and an integrated platform to optimise agents for biofilm activity
  • Learn about a unique antibiotic discovery engine and an integrated platform to optimise agents for biofilm activity
  • NEW & FUTURE DRUG DEVELOPMENTS: Hear about antimicrobial peptides, new classes of inhibitors and drugs in the development pipeline
  • STRATEGIES AGAINST RESISTANCE: Examine new ways to combat antibiotic resistance
  • UPDATE ON ANTI-VIRALS AND ANTI-FUNGALS: What are the current developments?
  • DATA EVALUATION & ANALYSIS: Identify how to apply advances in data-driven antibiotics research and learn how to increase the value of your surveillance data
  • Examine new ways to combat antibiotic resistance

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

William Weiss

William Weiss, Director, Drug Evaluation, Cumbre

9:10 NEXT GENERATION ANTI-VIRAL DRUG DISCOVERY AND DEVELOPMENT

Anita Howe

Anita Howe, Associate Director, Infectious Diseases, Wyeth

  • New anti-virals from old targets in HCV
  • Host cell targets in HCV therapy
  • Opportunities and challenges of emerging HCV targets
  • Resistance - a reality?
  • 9:50 SYSTEMIC FUNGAL PATHOGENS

    Laura Harris

    Laura Harris, Analyst, Datamonitor

  • The need for more data before products are used
  • An analysis of new product uptake
  • Niche markets
  • 10:30 Morning Coffee

    11:00 ADDRESSING KEY HURDLES IN EFFECTIVE ANTIBIOTIC DRUG DISCOVERY

    Dr Lloyd Czaplewski

    Dr Lloyd Czaplewski, Director, Research, Prolysis

  • Enhancing hit compound identification through neural net technology
  • Using whole cell screening assays
  • Application of microscopy to determine mechanism of action
  • Status of lead programmes
  • 11:40 ANTIMICROBIAL PEPTIDES

    Dr Per Holse Mygind

    Dr Per Holse Mygind, Anti-Infective Discovery, Novozymes

  • Introduction to antimicrobial peptides
  • Overview of technology platforms for discovery, optimisation and production of antimicrobial peptides
  • Novispirins for topical applications
  • Plectasin for systemic applications
  • 12:20 Networking Lunch

    13:50 INTEGRATED PLATFORM TO OPTIMISE AGENTS FOR BIOFILM ACTIVITY

    William Weiss

    William Weiss, Director, Drug Evaluation, Cumbre

  • Basis of bacterial biofilm infections
  • Scope of biofilm-associated infections/ current treatment regimens
  • Integrated platform for biofilm discovery research
  • In vitro / in vivo methodology
  • Optimised agents for biofilm infections
  • 14:30 PEPTIDE DEFORMYLASE INHIBITORS

    Kathryn Bracken

    Kathryn Bracken, Associate Director, Novartis Institute, BioMedical Research

  • Prospects for potent and selective PDF inhibitors as antibacterial agents
  • Lessons learned from phase I development of novel PDF inhibitors
  • Second generation peptide deformylase inhibitors
  • 15:10 Afternoon Tea

    15:40 ß-LACTAMASE INHIBITORS, V. 2005

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, Vice President, Infectious Diseases, Methygene

  • New developments in ß-lactamases
  • ß-lactam-based inhibitors: (oxa)penems, cephems, monobactams
  • Transition-state analogue inhibitor: boronate, phosphonates
  • New developments in ß-lactam-based inhibitors: sulfones
  • New developments in transition state analogues
  • The challenge of target access in gram-negative bacteria
  • Prospects for ß-lactamase inhibitors
  • 16:20 AMINOACYL-TRNA SYNTHETASE INHIBITORS

    Heike Broetz-Oesterhelt

    Heike Broetz-Oesterhelt, Senior Scientist, Antibacterial Research, Bayer Healthcare

  • Aminoacyl-tRNA synthetase as antibacterial targets
  • Update on natural products, substrate mimics and screening derived inhibitors
  • Phenyl-thiazolyl urea sulfonamides as potent inhibitors of bacterial phenylalanyl-tRNA synthetase
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Lloyd Czaplewski

    Dr Lloyd Czaplewski, Director, Research, Prolysis

    9:10 A NEW CLASS OF DUAL TARGETING GYRB/PARE ANTIBACTERIALS

    Dean Stamos

    Dean Stamos, Associate Director, Chemistry, Drug Discovery, Vertex Pharmaceuticals

  • Antimicrobial potency against clinically relevant pathogens including those resistant to current standards of care
  • Characterisation of dual inhibition including biochemical, genetic and structural evidence
  • Pharmacokinetic performance in multiple species
  • Pharmacological efficacy in numerous models of infection
  • Toxicological assessment
  • 9:50 ANTIBIOTIC SURVEILLANCE PLUS

    David Farrell

    David Farrell, Director, Medical & Molecular Microbiology, GR Micro

  • Resistance mechanism surveillance and identifying new mechanisms
  • The use of molecular epidemiology to track resistance clones
  • Serotyping: assessing the impact of vaccine introduction on resistance
  • Web-based access to data and data analysis
  • IT-based marketing tools and strategies
  • 10:30 Morning Coffee

    11:00 ADVANCES IN DATA-DRIVEN ANTIBIOTICS RESEARCH: NOVEL APPROACHES TO TARGET VALIDATION, ASSAY DEVELOPMENT AND COMPOUND EVALUATION

    Hans Peter Fischer

    Hans Peter Fischer, Chief Scientific Officer, Genedata

  • Guiding the development of innovative pathway-specific screening assays
  • Identifying and characterising potent small-molecule inhibitors using in silico methods
  • Discovering the mechanism-of-action of antibacterial agents through transcriptional profiling
  • Investigating pathway activation patterns to characterise drug resistance mechanisms
  • Evaluating and prioritising lead structures for chemical optimisation
  • 11:40 TO COMBAT ANTIBIOTIC RESISTANCE

    Jan Verhoef

    Jan Verhoef, Head, Eijkman Winkler Institute, ENARE

  • Public health impact of antimicrobial resistance in Europe
  • Biological weapons and antibiotic resistance
  • Surveillance of antibiotic resistance
  • Antibiotic consumption
  • Education and infection prevention
  • New antibiotics and mechanisms of resistance
  • The European research agenda and policy measures
  • 12:20 Networking Lunch

    14:00 A NEW STRATEGY TO OPTIMISE ANTIBIOTIC THERAPY

    Marion Carson

    Marion Carson, Managing Director, IPSAT Therapies

  • Medical unmet needs in anti-microbials
  • Focusing on hospital infections and anti-microbial resistance
  • New solutions for IV antibiotic class
  • Drug development overview with focus on safety and efficacy
  • Overview of current clinical trials
  • 14:40 MODE OF ACTION AND RESISTANCE OF KETOLIDES

    Andre Bryskier

    Andre Bryskier, Head, Clinical Pharmacology, Anti-Infectives, Sanofi-Aventis

  • Ketolide: innovative compounds
  • Needs for new compounds
  • Status of Erythromycin A resistance worldwide for gram-positive cocci
  • Ribosomal interactions
  • Bacterial defence
  • Ketolide future
  • 15:20 GENETICS OF PANDEMIC INFLUENZA VIRUS 1918

    John Oxford

    John Oxford, Professor, Virology & Scientific Director, The Royal London Hospital & Retroscreen Virology Ltd

  • The x-ray crystal structure of the HA and its biological properties
  • The new class of anti-virals – the neuramidase inhibitors
  • Chicken flu H5N1
  • What is happening in South East Asia and Japan?
  • What has to be done for the future?
  • 16:00 Chairman’s Closing Remarks and Close of Day One

    +

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.